Arena Pharma Could Be Developing Several Best-In-Class Agents
May 19, 2017 at 14:59 PM EDT
Leerink initiated coverage of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) with an Outperform rating and a $5 price target. New ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.